15 July 2019
Luxembourg, July 15, 2019 – Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of high unmet patient need, today announces the fund’s first exit since launching in 2016.
5 September 2017
AMAL Therapeutics raises €8 million (CHF 8.8 million) in first closing of Series B financing round
Thank you for your form submission, we will get in contact with you shortly.